What is NAD+ Precursors (NMN/NR)?

NAD+ precursors here refers mainly to nicotinamide riboside and nicotinamide mononucleotide, vitamin B3-related compounds used to raise NAD+ pools. [1][2][3]

These are not peptides. They appear in peptide catalogs because they are often stacked with mitochondrial and longevity peptides such as MOTS-c and 5-Amino-1MQ. [1][2][3]

The evidence is strongest for changing NAD-related biomarkers, while durable outcomes for longevity, weight loss, cognition, or disease prevention remain less settled. [1][2][3]

What NAD+ Precursors (NMN/NR) is investigated for

NAD+ Precursors (NMN/NR) evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

NAD+ biomarker restoration

Oral

66% Moderate

NAD+ biomarker restoration has the strongest and most specific NAD precursor evidence. [1][11][4]

Human evidence

Human studies show that NAD precursors can raise NAD-related biomarkers in blood or tissue compartments, including acute cerebral NAD+ measurements. [1][11][4]

Animal / mechanistic evidence

Mechanistic reviews support NAD salvage and precursor metabolism as the basis for biomarker changes. [1][11][4]

Metabolic and cardiometabolic outcomes

Oral, Injectable

54% Emerging

Metabolic benefits are less certain than NAD biomarker increases and should be graded separately. [2][14][15]

Human evidence

Human NMN and NR studies report mixed metabolic and cardiometabolic outcomes, including triglyceride and cardiometabolic-health discussions. [2][14][15]

Animal / mechanistic evidence

NAD metabolism, gut microbiome, and cardiometabolic reviews support mechanistic plausibility. [2][14][15]

Fatigue and physical performance

Oral

52% Emerging

Fatigue and performance are human-studied but modest and population-specific. [3][6]

Human evidence

A randomized trial in older Japanese adults evaluated sleep quality, fatigue, and physical performance after NMN intake, and a meta-analysis reviewed skeletal muscle outcomes. [3][6]

Animal / mechanistic evidence

The rationale is mitochondrial and skeletal-muscle NAD biology rather than a stimulant-like effect. [3][6]

Healthy-aging and DNA-repair signaling

Oral, Injectable

42% Preliminary

Healthy-aging and DNA-repair claims are pathway-level and preliminary. [8][16][7]

Human evidence

Human longevity-outcome evidence is not established; recent reviews describe anti-aging and wellness evidence as mixed and still emerging. [8][16][7]

Animal / mechanistic evidence

NAD+ biology supports sirtuin, mitochondrial, and DNA-repair pathways, but pathway activation does not prove lifespan or disease-prevention benefit. [8][16][7]

Evidence snapshot

Overall confidence

Moderate

66%

Oral NR and NMN have the clearest support for moving NAD-related biomarkers. Durable metabolic, longevity, or injectable NAD+ outcomes remain more uncertain. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

66%

Human evidence

Moderate

Human studies support increases in NAD-related biomarkers for some oral precursor products. Clinical outcome effects are less consistent. [1][2][3][4]

34%

Animal / preclinical

Limited

Mechanistic pathways directly support NAD salvage, mitochondrial metabolism, and stress-response plausibility. [1][2][3][4]

66%

Mechanism support

Moderate

NR and NMN feed NAD+ salvage pathways, increasing availability of NAD-related metabolites used in mitochondrial energy metabolism, DNA repair, and sirtuin-linked signaling. [1][2][3][4]

Forms & administration

NAD+ precursor content separates oral NR/NMN supplement products from injectable or infusion NAD+ compounding discussions. Route and product category determine what can be tracked. [19][20][1]

OralInjectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Oral NR and NMN products use formulation-specific milligram labels. Injectable or infusion NAD+ belongs to a separate sterile-compounding protocol rather than an oral supplement range. [19][20][1]

Frequency

Oral products are commonly daily; injectable or infusion schedules are protocol-specific. [19][20][1]

Timing Considerations

Morning timing is the common oral anchor so energy, sleep, and stimulant overlap are easier to interpret. [19][20][1]

Cycle Length

NAD-related blocks usually need a clinician-directed review window long enough to compare fatigue, sleep, and biomarker patterns. [19][20][1]

What to expect

First week

Oral NAD+ precursor use may feel like changes in daytime energy, sleep rhythm, exercise tolerance, or recovery from ordinary workload. [1][2][3][4][19][20]

Weeks 4-8

Oral precursor blocks may show changes in energy, exercise tolerance, glucose, lipids, and NAD-related biomarker patterns. [1][2][3][4][19][20]

After stopping

Biomarker and energy patterns may drift toward baseline intake and lifestyle after oral NAD+ precursor use ends. [1][2][3][4][19][20]

Safety profile

NAD+ precursor safety is route-specific: oral NR/NMN supplement use differs from injectable or IV NAD+ sterile-compounding risk. [19][1][2][3]

Common side effects

GI upset [19][1][2][3]
Flushing [19][1][2][3]
Headache [19][1][2][3]

Cautions

Injectable / IV NAD+ [19][1][2][3]
Cancer / metabolism [19][1][2][3]
Liver / kidney / meds [19][1][2][3]

What we don't know

Long-term high-dose oral use, injectable protocols, disease-specific outcome benefits, and product-to-product equivalence remain uncertain. [19][1][2][3]

Who NAD+ Precursors (NMN/NR) is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding without clinician review
Pregnancy or breastfeeding without clinician review warrants medical review or avoidance for NAD+ Precursors (NMN/NR). [19][1][2][3]
Active cancer without specialist review
Active cancer without specialist review warrants medical review or avoidance for NAD+ Precursors (NMN/NR). [19][1][2][3]
Severe liver disease without clinician oversight
Severe liver disease without clinician oversight warrants medical review or avoidance for NAD+ Precursors (NMN/NR). [19][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Glucose / metabolic drugs
Insulin, GLP-1 drugs, metformin, or other metabolic therapies can make energy, glucose, and weight signals harder to attribute; this is a metabolic caution. [19][1][2][3]
Niacin / methyl-donor stacks
Niacin, high-dose B-complex, methyl donors, or NAD+ stacks can add flushing, GI upset, or sleep changes; this is a theoretical supplement pathway caution. [19][1][2][3]
IV admixtures / compounded injectables
Injectable NAD+ mixed with other IV ingredients adds sterility, endotoxin, and compatibility uncertainty; this is a product-quality caution. [19][1][2][3]
Oncology / metabolic therapies
Cancer therapies or experimental metabolic drugs can make NAD-pathway effects difficult to interpret; this is a theoretical pathway caution. [19][1][2][3]

Pairing notes

Commonly included in these stacks

NAD+ / MOTS-c / 5-Amino-1MQ

NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. NAD+ support targets redox and energy pools, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism.

NAD+MOTS-c5-Amino-1MQ

Regulatory status

United States

In the U.S. as of 2026-06-21, NAD+ precursor supplement availability is separate from FDA drug approval. Injectable or IV NAD+ compounding has FDA sterile-compounding warnings, and no reviewed route here should be treated as an FDA-approved drug use. [20][21][24][25]

Route	FDA drug approval	503A compounding
Oral	Not Approved NAD+ Precursors is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [20][21][24][25]	Not Listed NAD+ Precursors is not in the current reviewed 503A compounding bucket for the oral route; compounding status is separate from FDA drug approval. [20][21][24][25]
Injectable	Not Approved NAD+ Precursors is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [20][21][24][25]	Not Listed Injectable or IV NAD+ compounding is not FDA approval; FDA has warned that food-grade NAD+ ingredients are not suitable for sterile compounding because of contamination and endotoxin concerns. [19][20][21][24][25]

Oral

FDA drug approval

Not Approved

NAD+ Precursors is not FDA-approved as an oral drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [20][21][24][25]

503A compounding

Not Listed

NAD+ Precursors is not in the current reviewed 503A compounding bucket for the oral route; compounding status is separate from FDA drug approval. [20][21][24][25]

Injectable

FDA drug approval

Not Approved

NAD+ Precursors is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [20][21][24][25]

503A compounding

Not Listed

Injectable or IV NAD+ compounding is not FDA approval; FDA has warned that food-grade NAD+ ingredients are not suitable for sterile compounding because of contamination and endotoxin concerns. [19][20][21][24][25]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [27][28][29][30]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat NAD+ Precursors oral and injectable routes as athlete-cleared without sport-specific review. [22][20][21][24][25]

How it works

NR and NMN feed NAD+ salvage pathways, increasing availability of NAD-related metabolites used in mitochondrial energy metabolism, DNA repair, redox balance, and sirtuin-linked signaling. In plain terms, they try to raise a cellular cofactor pool. [1][2][3][4]

Oral supplement exposure is not the same as injectable NAD+ or infusion protocols. Raising NAD-related biomarkers does not prove longevity benefit; the practical question is whether the route and product translate into measurable function, metabolic health, or disease outcomes. Benefit depends on more than the NAD+ number. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about NAD+ Precursors (NMN/NR):

A key evidence gap is hard outcome trials beyond NAD biomarkers. [1][2][3][4]

A key evidence gap is long-term high-dose safety. [1][2][3][4]

A key evidence gap is injectable NAD+ pharmacology and sterile-product safety. [1][2][3][4]

Common questions

Are NAD+ precursors peptides?

No. NMN and NR are vitamin B3-related NAD+ precursors, not peptides. [20][21][19][1]

Do NR and NMN raise NAD+?

Yes. Human studies support NAD-related biomarker increases for some NR/NMN products, but route, product, and clinical outcomes remain separate questions. [20][21][19][1]

Is injectable NAD+ the same as oral NR or NMN?

No. Injectable sterile compounded products have different exposure, safety, and regulatory concerns from oral NR or NMN supplements. [20][21][19][1][24]

Myths & misconceptions

Myth

Higher NAD+ automatically means longer life.

Reality

Biomarker movement does not establish lifespan extension. [1][2][3][4]

Myth

NR, NMN, and NAD+ injections are interchangeable.

Reality

They differ by chemistry, route, exposure, and safety profile. [1][2][3][4]

History & discovery

NAD+ precursor interest grew from metabolism and aging biology showing that NAD-related pathways connect energy metabolism, DNA repair, redox balance, and stress response. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]

Human studies tested whether oral NR or NMN can raise NAD-related metabolites and affect triglycerides, fatigue, sleep, or physical performance. Biomarkers became the main bridge to claims. [1][2][3][4]

Consumer use expanded into longevity stacks while injectable NAD+ clinics created a separate route and safety story. That split matters because oral precursors and sterile infusions are not interchangeable. [1][2][3][4]

Published research 22 studies

[1]

Acute nicotinamide riboside supplementation increases human cerebral NAD(+) levels in vivo.

Magn Reson Med, 2024 Dec. human clinical.

[2]

Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals.

Cureus, 2022 Sep. review.

[3]

Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.

Nutrients, 2022 Feb 11. human clinical.

[4]

Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.

J Gerontol A Biol Sci Med Sci, 2023 Dec 1. review.

[5]

NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.

Exp Gerontol, 2020 Apr. review.

[6]

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.

J Cachexia Sarcopenia Muscle, 2025 Jun. review.

[7]

Emerging strategies, applications and challenges of targeting NAD(+) in the clinic.

Nat Aging, 2025 Sep. review.

[8]

NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.

Ageing Res Rev, 2026 Apr. review.

[9]

Supplementation with NAD+ Precursors for Treating Alzheimer's Disease: A Metabolic Approach.

J Alzheimers Dis, 2024. review.

[10]

The acute effect of different NAD(+) precursors included in the combined metabolic activators.

Free Radic Biol Med, 2023 Aug 20. human clinical.

[11]

The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans.

Nat Metab, 2026 Jan. human clinical.

[12]

NAD(+) enhancers as therapeutic agents in the cardiorenal axis.

Cell Commun Signal, 2024 Nov 8. review.

[13]

Novel insight into nicotinamide adenine dinucleotide and related metabolites in cancer patients undergoing surgery.

Sci Rep, 2024 Jul 17. human clinical.

[14]

NAD+-Increasing Strategies to Improve Cardiometabolic Health?

Front Endocrinol (Lausanne), 2021. review.

[15]

Metabolic Disease, NAD Metabolism, Nicotinamide Riboside, and the Gut Microbiome: Connecting the Dots from the Gut to Physiology.

mSystems, 2022 Feb 22. human clinical.

[16]

NAD(+) Precursors in Human Health and Disease: Current Status and Future Prospects.

Antioxid Redox Signal, 2023 Dec. review.

[17]

NAD(+) and NAFLD - caution, causality and careful optimism.

J Physiol, 2022 Mar. review.

[18]

Implications of NAD(+) boosters in translational medicine.

Eur J Clin Invest, 2020 Oct. review.

[19]

FDA reminds compounders to use ingredients suitable for sterile compounding

U.S. Food and Drug Administration. official guidance.

[20]

Drugs@FDA/openFDA query for NAD+ Precursors (NMN/NR)

U.S. Food and Drug Administration. database query.

[21]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[22]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.